Associations between soluble PD-L1/PD-1 and circulating immune cells for prostate cancer progression

被引：0
|
作者：
Survila, Zilvinas [1 ]
Pasukoniene, Vita [2 ]
Zvirble, Margarita [2 ,3 ]
机构：
[1] Vilnius Univ, Life Sci Ctr, Inst Biosci, Vilnius, Lithuania
[2] Natl Canc Inst, Vilnius, Lithuania
[3] Vilnius Univ, Life Sci Ctr, Vilnius, Lithuania
来源：
EUROPEAN JOURNAL OF IMMUNOLOGY | 2024年 / 54卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
2251 - P3.
引用
收藏
页码：1630 / 1630
页数：1
相关论文
共 50 条
  • [21] The role of PD-1/PD-L1 axis and macrophage in the progression and treatment of cancer
    Jiajing Cai
    Qi Qi
    Xuemeng Qian
    Jia Han
    Xinfang Zhu
    Qi Zhang
    Rong Xia
    Journal of Cancer Research and Clinical Oncology, 2019, 145 : 1377 - 1385
  • [22] Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
    Bai, Jie
    Gao, Zhitao
    Li, Xiang
    Dong, Liang
    Han, Weidong
    Nie, Jing
    ONCOTARGET, 2017, 8 (66) : 110693 - 110707
  • [23] PD-1/PD-L1 axis importance and tumor microenvironment immune cells
    Lotfinejad, Parisa
    Kazemi, Tohid
    Mokhtarzadeh, Ahad
    Shanehbandi, Dariush
    Niaragh, Farhad Jadidi
    Safaei, Sahar
    Asadi, Milad
    Baradaran, Behzad
    LIFE SCIENCES, 2020, 259
  • [24] PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy
    Dermani, Fatemeh K.
    Samadi, Pouria
    Rahmani, Golebagh
    Kohlan, Alisa K.
    Najafi, Rezvan
    JOURNAL OF CELLULAR PHYSIOLOGY, 2019, 234 (02) : 1313 - 1325
  • [25] Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer
    Iosune Baraibar
    Ignacio Melero
    Mariano Ponz-Sarvise
    Eduardo Castanon
    Drug Safety, 2019, 42 : 281 - 294
  • [26] PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
    Hartkopf, Andreas D.
    Taran, Florin-Andrei
    Wallwiener, Markus
    Walter, Christina B.
    Kraemer, Bernhard
    Grischke, Eva-Maria
    Brucker, Sara Y.
    BREAST CARE, 2016, 11 (06) : 385 - 390
  • [27] Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer
    Baraibar, Iosune
    Melero, Ignacio
    Ponz-Sarvise, Mariano
    Castanon, Eduardo
    DRUG SAFETY, 2019, 42 (02) : 281 - 294
  • [28] PD-1/PD-L1 Axis in Lung Cancer
    Santini, Fernando C.
    Hellmann, Matthew D.
    CANCER JOURNAL, 2018, 24 (01): : 15 - 19
  • [29] Characteristics of Soluble PD-L1 and PD-1 Expression and Their Correlations With Immune Status and Prognosis in Advanced Lung Cancer
    Li, Ran
    Liang, Hongge
    Shang, Ying
    Yang, Zhengwu
    Wang, Keqiang
    Yang, Donghong
    Bao, Jing
    Xi, Wen
    Zhou, Dexun
    Ni, Wentao
    Gao, Zhancheng
    Mu, Xinlin
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2025,
  • [30] PD-1/PD-L1 Inhibitors in Cervical Cancer
    Liu, Yuncong
    Wu, Li
    Tong, Ruizhan
    Yang, Feiyue
    Yin, Limei
    Li, Mengqian
    You, Liting
    Xue, Jianxin
    Lu, You
    FRONTIERS IN PHARMACOLOGY, 2019, 10
12345